Clinical Trial Update: Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating pharmacokinetics, efficacy, and safety of RI-002 intravenous immunoglobulin in subjects with primary immunodeficiency diseases. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• RI-002 (intravenous immunoglobulin)

Snippet

Sponsor: ADMA Biologics, Inc. | Conditions: Primary Immune Deficiency Disorder | Phase 3 | Status: COMPLETED | Results posted: 2016-10-05